TABLE 1.
Significant differences in marker expression between total cohorts of acute promyelocytic leukemia and NPM1+ acute myeloid leukemia
| Marker | APL mean % positive cells in CD33+/++ gate (range) | APL no. of positive cases (%) | NPM1+ AML mean % positive cells in CD33+/++ gate (range) | NPM1+ AML no. of positive cases* (%) | p value for % positive cells in CD33+/++ gate | p value for MFI |
|---|---|---|---|---|---|---|
| CD2 | 26% (0–86%) | 22 (42.3) | <1 | 0 | .001 | NA |
| CD11b | 5% (0–65%) | 3 (5.8) | 27% (1–95%) | 14 (44) | <.001 | NS |
| CD11c | 36% (0–97%) | 26 (50) | 72% (3–96%) | 29 (91) | <.001 | <.001 |
| CD13 | 97% (67–100%) | 52 (100) | 69% (2–100%) | 29 (91) | <.001 | <.001 |
| CD14 | <1 | 0 | 11% (0–93%) | 5 (16) | <.001 | NA |
| CD15 | 1% (0–30%) | 2 (3.8) | 19.5% (0–74%) | 12 (37) | <.001 | <.001 |
| CD36 | <1 | 0 | 27% (0–95%) | 15 (47) | <.001 | NA |
| CD64 | 95% (71–100%) | 52 (100) | 55% (0–99%) | 26 (81.3) | <.001 | .034 |
| CD123 | 25% (0–88%) | 17 (33%) | 37% (0–96%) | 20 (63) | .034 | .015 |
| HLA‐DR | 21% and 43% | 2 (3.9) | 37% (0–88%) | 20 (63) | <.001 | NS |
Note: APL n = 52, NPM1 AML n = 32.
Abbreviations: AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; MFI, mean fluorescence intensity; NA, not available; NS, not significant, Mann–Whitney test.